Literature DB >> 16971268

The diagnosis and treatment of hepatopulmonary syndrome.

M Susan Mandell1.   

Abstract

Few prognostic indicators and outcomes reported for patients who have hepatopulmonary syndrome can be consistently reproduced between institutions. The lack of practice recommendations based upon consistent and predictable outcomes creates uncertainty for physicians trying to make the best patient choices. With the scarcity of donor organs, these issues are of particular importance when transplantation in considered as a treatment option. Much uncertainty arises from the basic tasks of making an accurate diagnosis in patients who have symptoms suggestive of hepatopulmonary syndrome. This article focuses on problems that underlie diagnostic accuracy and uses this information to appraise critically outcomes literature.

Entities:  

Mesh:

Year:  2006        PMID: 16971268     DOI: 10.1016/j.cld.2006.05.007

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  5 in total

1.  Pulmonary artery embolotherapy in a patient with type I hepatopulmonary syndrome after liver transplantation.

Authors:  Hae Won Lee; Kyung-Suk Suh; Joohyun Kim; Woo Young Shin; Nam-Joon Yi; Hwan Jun Jae; Jin Wook Chung; So Won Oh; Keon Wook Kang; Kuhn Uk Lee
Journal:  Korean J Radiol       Date:  2010-06-21       Impact factor: 3.500

2.  Hepatopulmonary syndrome: use of extracorporeal life support for life-threatening hypoxia following liver transplantation.

Authors:  Geoffrey M Fleming; Timothy T Cornell; Theodore H Welling; John C Magee; Gail M Annich
Journal:  Liver Transpl       Date:  2008-07       Impact factor: 5.799

3.  The ET-1-mediated carbonylation and degradation of ANXA1 induce inflammatory phenotype and proliferation of pulmonary artery smooth muscle cells in HPS.

Authors:  Jing He; Bin Yi; Yang Chen; Qing Huang; Huan Wang; Kaizhi Lu; Weiling Fu
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

4.  Annexin A1 protein regulates the expression of PMVEC cytoskeletal proteins in CBDL rat serum-induced pulmonary microvascular remodeling.

Authors:  Bin Yi; Jing Zeng; Guansong Wang; Guisheng Qian; Kaizhi Lu
Journal:  J Transl Med       Date:  2013-04-15       Impact factor: 5.531

5.  Hepatopulmonary syndrome and portopulmonary hypertension.

Authors:  Adrian Hendrickse; Fareed Azam; M Susan Mandell
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.